ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1578

Symptom Burden Among Immunoglobulin A Nephropathy (IgAN) Patients in a US Real-World Setting

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Perkins, Robert M., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Aldworth, Carolina A R, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
  • Przybysz, Raymond, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Doherty, Jim P., Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
  • Olson, Stephen W., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • George, Aneesh T., Novartis Healthcare Pvt. Ltd., Hyderabad, India
  • Das, Jaydeep, Novartis Healthcare Pvt. Ltd., Hyderabad, India
  • Studer, Rachel, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
Background

Immunoglobulin A nephropathy (IgAN) is the most prevalent chronic glomerulonephritis and 15-40% of patients will progress to end stage kidney disease (ESKD) within 10-20 years of diagnosis. The symptom burden by eGFR and proteinuria levels has not been well described in IgAN and is presented here.

Methods

This is a descriptive, retrospective study of adult (≥ 18 years) patients in de-identified Optum® Electronic Health Records (2007-2019). Pre-processed physician notes were used to select patients with at least two IgAN records without any secondary or negative notion. Patients without a record of renal biopsy, valid eGFR and proteinuria levels, or with a history of ESKD/kidney transplant were excluded. The demographic and clinical characteristics, including symptoms up to 12 months before and up to the 1st record of IgAN are presented here; these symptoms were stratified by eGFR and proteinuria levels.

Results

The final cohort consisted of 846 patients with a mean age of 48.5 years; 57.7% were male and 7.0% Asian. Proteinuria levels of ≥1 g/day were found in 35.7% of patients. The median eGFR was 39.0 ml/min/1.73m2, median creatinine was 1.8 mg/dL, and 20.8% of patients had severe deterioration of kidney function (eGFR <15). Overall, more patients in higher chronic kidney disease (CKD) stages experienced any given symptom but this trend was not as consistent for higher proteinuria levels.

Conclusion

Our study found that a considerable proportion of patients experienced pain, fatigue and edema. Except in a few instances, all symptoms increased with lower eGFR levels but this trend was less apparent for proteinuria. Our overall findings suggest that a relatively large proportion of IgAN patients, even those with preserved kidney functions could be experiencing substantial symptomatic burden and this warrants further investigation.

Funding

  • Commercial Support